

2014 INDIANA GENERAL ASSEMBLY

- HB 1218 – Drug Treatment and Reporting, Sales of Insulin*
 - Author: Rep. Steve Davisson, R-Salem
 - Sponsor: Sen. Patricia Miller, R-Indianapolis
 - ISMA Initiative, Supported
 - Expires standards for operation rules concerning prior authorization for a take home supply of opioid treatment medication
 - Current law requires rules to require prior authorization for more than 14 days of medication
 - Prohibits an opioid treatment program from prescribing, dispensing, or providing more than a seven day supply of opioid treatment medication to a patient to take out of the facility

*Designates an ISMA Resolution



2014 INDIANA GENERAL ASSEMBLY

- **HB 1218 (Continued)**

- Requires an opioid treatment program to follow the standards and protocols adopted by the division of for each opioid treatment program patient
- Requires the dispenser at an opioid treatment program to transmit certain information to the division within specified time frames
- Provides that the information is subject to federal patient confidentiality regulations
- Requires a provider to release certain information from a committed patient's mental health records upon request of a court



2014 INDIANA GENERAL ASSEMBLY

- HB 1218 (Continued)
 - Requires the Indiana professional licensing agency to study the impact of including all prescription drugs in the INSPECT program and sets forth requirements of the study.
 - Requires the legislative council to assign a committee to study:
 - Security of the INSPECT program
 - If opioid treatment programs should be prohibited from allowing patients to take home opioid treatment medication
 - Prohibits the sale of insulin without a prescription from an authorized provider

